ESMO 2025 – Potomac marches step for step with Crest
Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.
ESMO 2025 – Lilly strengthens Verzenio’s case
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
ESMO 2025 – J&J brings a new Rybrevant use into the fold
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
ESMO 2025 – Boehringer and Bayer eye the front line
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
